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Introduction
P
atients with cirrhosis develop complications 
in  a  variety  of  organs  including  the  heart, 
lungs, kidneys, and other organ systems. A variety 
of  causes  for  cardiac  and  pulmonary  dysfunction 
in  liver  disease  have  been  identified  and  include 
intrinsic cardiopulmonary disorders not specifically 
related to liver disease, as well as unique problems 
associated with the presence of liver disease and/or 
portal hypertension.
Owing to the success of orthotopic liver transplantation 
(OLT), there has been increasing recognition of the 
importance  of  the  cardiac  and  pulmonary  vascular 
complications of hepatic disease states.
Pulmonary complications include hepatopulmonary 
syndrome,  hepatic  hydrothorax,  and  pulmonary 
hypertension  (1-3).  In  screening  studies  of  patients 
with  chronic  liver  disease,  arterial  blood  gas  (ABG) 
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Background and Aims: The determination of the prevalence of cardiopulmonary complications at a liver transplant center 
in Iran.
Methods: Ninety-nine patients (61 male and 38 female) with a mean age of 36.5 (15-66) years with proven cirrhosis 
were enrolled in this study. Patients with primary cardiac disease, current smokers, those with sepsis, hepatocellular 
carcinoma, recently ruptured esophageal varices and chronic pulmonary or renal diseases were excluded from the study.
Sixty-nine patients had ascites. Forty-four patients had grade C Child-Pugh classification.
All patients were evaluated for respiratory function by chest X-ray (CXR), room air arterial blood gas, simultaneous pulse 
oximetry, cardiac echocardiography and spirometry.
Results: Sixty-one patients (66.1%) had a widened alveolar-arterial O2 difference ( > 20 mmHg); 14 (14.1%) had hypoxemia;   
6 (6.1%) had mean pulmonary arterial pressure (MPAP) = 25-40 mmHg; 12 (12.1%) had tricuspid regurgitation; pleural 
effusion and lung restriction were detected in 4 (4%) and 50 (50.5%), respectively. P(A-a)O2 was negatively associated with 
pulmonary hypertension (P < 0.03) and tricuspid regurgitation (P < 0.005). Portal hypertension and portal vein thrombosis 
were detected in 91 and 8 patients, respectively.
Conclusions: A widened alveolar-arterial oxygen difference was common in our patients, but hypoxemia occurred in 14% 
of patients. Portopulmonary hypertension was preponderant in those patients of male gender.
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abnormalities are found in as many as 45% of patients, 
and abnormal pulmonary function tests in as many as 
50% (4).
Cardiac complications are hemodynamic changes, 
such as increased cardiac output and regional organ 
blood  flow,  decreased  arterial  pressure,  and  low 
peripheral vascular resistance (5).
This study reports the frequency of pulmonary 
complications in a population of cirrhotic patients 
undergoing preoperative liver transplant evaluation.
Materials and Methods
Patients
In a cross-sectional study, ninety-nine consecutive 
patients  (61  male,  38  female,  age  15-66,  mean 
age  39.65  ±  11.65)  with  histologically  proven 
cirrhosis,  who  were  on  a  liver  transplantation 
waiting  list  at  Shiraz  Transplant  Center,  were 
evaluated.  Exclusion  criteria  were:  recently 
ruptured  esophageal  varices,  primary  cardiac 
disease, chronic bronchopulmonary disease, renal 
disease, sepsis, current smoking and hepatocellular 
carcinoma. The etiologies of cirrhosis were: viral in 
38 (hepatitis B:34, hepatitis C:4); cryptogenic in 
26; autoimmune hepatitis in 13; primary sclerosing 
cholangitis in 12; and other less frequent causes in 
10 patients. The severity of cirrhosis was assessed 
according to the Child-Pugh classification. There 
were 8 grade A (8.1%), 47 grade B (47.5%) and 44 
grade C (44.4%) patients. Portal hypertension was 
detected in 91 patients, and portal vein thrombosis 
in 8 patients.
Meseaurments
Arterial  blood  gas,  pulse  oximetry,  chest 
radiography,  doppler  echocardiography,  doppler 
sonography  of  portal  vein,  spirometry  and  liver 
function  tests  were  performed  on  all  patients. 
Hypoxemia  was  considered  when  PaO2  <  70 
mmHg. Mean pulmonary arterial pressure (MPAP) 
was calculated based on the tricuspid regurgitation 
gradient; and pulmonary hypertension was considered 
when MPAP > 25 mmHg, and portal hypertension 
was defined as flow velocity < 20 cm/s by doppler 
sonography.
Statistical analysis
The  results  are  expressed  as  mean  ±  standard 
deviation.  The  chi-square  test,  Fisher  exact  test 
andthe bivariate correlation test were used, where 
appropriate, to analyze the data provided. SPSS ver. 
11.50 was used for statistical analysis. Changes were 
reported as significant if P < 0.05.
Results
Hypoxemia  and  alveolar-arterial  oxygen  pressure 
difference
Sixty-one  patients  (66.1%)  had  a  widened 
alveolar-arterial  oxygen  difference  (>  20  mmHg) 
(41  male  and  20  female,  mean  age  40.36);  42 
(73.8%) had ascites. The proportion of patients with 
pulmonary hypertension in the widened P (A-a) O2 
group  (1/61)  was  significantly  lower  than  in  the 
normal P(A-a)O2 group (5/38) (P = 0.03).
Fifty-four  percent  of  patients  with  abnormal 
P(A-a)O2 had lung restriction. All of the hypoxemic 
patients (14.1%) were in the abnormal P (A-a) O2 
group (P = 0.001). The proportion of patients with 
tricuspid  regurgitation  in  the  normal  P(A-a)O2 
group (9 /38) was greater than in the abnormal group 
(3/61) ( P = 0.009). There was a significant positive 
correlation  between  P(A-a)O2  and  prothrombin 
time (P = 0.03)(r= 0.274).
A widened P(A-a)O2 has no association with the 
etiology and severity of cirrhosis, age, sex, blood group, 
ascites, lung volume, portal hypertension, portal vein 
thrombosis, serum albumin and bilirubin.
The proportion of patients with hypoxemia was 
significantly  greater  in  the  Child-Pugh  grade  C 
patients(11/44),  than  in  the  Child-Pugh  grade  B 
patients(3/47) or in the Child-Pugh grade A patients 
(0/8) (P = 0.019). None of the hypoxemic patients 
had pulmonary hypertension or pleural effusion.
The mean PaCO2 were 35.06 ± 4.54 which was 
lower  in  those  patients  with  abnormal  P(A-a)O2 
(32.86 ± 4.91 vs. 36.50 ± 5.51)(table 1).
Lung restriction
Fifty patients in this study had lung restriction 
(32 male, 18 female, mean age 40.26) out of which 
24 (48%) showed mild, and 14 (28%) tense, ascites 
and 12 (24%) were without ascites. This showed no 
significant association between lung restriction and 
ascites, except for tense ascites (P = 0.04).
Thirty  patients  (66%)  with  restrictive  lung 
disease had widened P(A-a)O2 without significant 
association.  There  was  no  significant  association 
between lung restriction and the severity and etiology 
of cirrhosis, sex, blood group, portal hypertension, 
portal vein thrombosis, bilirubin and prothrombin 
time. There  was  a  significant  correlation  between 
pleural  effusion  and  moderate  or  severe  lung 
restriction (6) (P = 0.033).
Pulmonary hypertension
  Six  patients  (6.1%)  (4  male,  2  female)  had 
MPAP  >  25  mmHg,  4  in  Child-Pugh  grade  B 
and 2 in Child-Pugh grade C, without right atrial Hepatitis Monthly, Spring 2010; 10(2): 105-109
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Discussion
Most patients in this study showed one or more 
types of cardiopulmonary complications. Pulmonary 
complications were: widened alveolar-arterial oxygen 
difference;  ventilatory  restriction;  and  hepatic 
hydrothorax.  Cardiovascular  complications  were: 
pulmonary hypertension; and tricuspid regurgitation. 
The most common pulmonary complication in this 
study was widened P(A-a)O2(61.5%), which was four 
times greater than hypoxemia; this may be related to 
pulmonary arteriovenous shunting, portopulmonary 
shunting, and intrapulmonary vascular abnormalities, 
limited  diffusion  of  oxygen,  and/or  ventilation-
perfusion  mismatching  (7).  Different  reports  have 
given different frequencies of reduced arterial oxygen 
saturation  in  cirrhotic  patients  varying  from  about 
10% to as high as 70% (8).In a prospective study by 
Vachiery et al. (9), 14% of 120 cirrhotic patients had 
a PaO2 of < 70 mmHg, and this hypoxemic subset 
was characterized by more severe liver failure with a 
higher Child-Pugh score and a higher proportion of 
grade C disease. In another study by Yigit et al. (10) the 
frequency of hypoxia was found to be 33.3%, with the 
same threshold of hypoxia, which is markedly more 
than in our study (14%),which might be the result of 
different characteristics of patient populations.
There was a greater frequency of alveolar- arterial 
oxygen difference than hypoxemia, since normoxemia 
can be maintained by alveolar hyperventilation, even 
with a widened P(A-a)O2. 
In our study, there was widened P(A-a)O2 in 
66% of patients, and hypoxia in 14%. There was 
no  significant  difference  in  Child–Pugh  grade 
between  the  abnormal  P(A-a)O2  group  and  the 
normal  P(A-a)O2  group,  indicating  that  the 
severity of cirrhosis does not play a major role in 
the  development  of  P(A-a)O2,  but  hypoxemia 
occurs more in Child–Pugh grade C. This finding 
suggests that the widened P(A-a)O2 occurs in the 
early stages of cirrhosis, with the same frequency as 
in the late stages, but that hypoxemia occurs mostly 
in the late stages of cirrhosis. This is consistent with 
previous reports (7, 9, 11-13).
In their study, Krowka et al.  (14) reported that 
there was no significant relationship between hypoxia 
and biochemical parameters (PT, albumin, bilirubin, 
and aminotransferases) of liver function. Similarly, 
there  were  no  significant  differences  between  the 
biochemical parameters of liver function and hypoxia 
in  our  patients,  except  for  a  positive  correlation 
between P(A-a)O2 and prothrombin time (P = 0.03)
(r= 0.274).
Different reports have given different frequencies 
of  ventilatory  restriction  in  cirrhotic  patients, 
varying from about 9% (15, 16) to as high as 24% (17), 
which may be the result of interstitial lung edema, 
ascites, and pleural fluid. In our study, 50 patients 
(50.5%) showed ventilatory restriction, significantly 
associated with tense ascites (P = 0.04).
Since patients with advanced liver disease usually 
hyperventilate,  hypocapnia  (PaCO2<35  mmHg) 
and respiratory alkalosis are common (13, 18, 19). In 
our  study  most  patients  had  respiratory  alkalosis, 
which was greater in the subgroup of patients with 
widened P(A-a)O2.
Portopulmonary  hypertension  (PPHTN)  is  an 
uncommon, but serious complication of cirrhosis, 
and  is  associated  with  a  grave  prognosis.  The 
incidence of PPHTN has been reported to be in a 
range of 0.25% to 6% (8, 20). McDonnell et al. (21) 
reviewed the results of 17,901 autopsies and found 
that  primary  pulmonary  hypertension  occurred 
in 0.13% of all patients but in 0.73% of patients 
with cirrhosis. In another study by Benjaminov et al. 
(22), the prevalence of PPHTN in cirrhotic patients 
with  refractory  ascites  was  found  to  be  16.1%. 
In  the  present  study,  the  prevalence  of  moderate 
PPHTN(25-40  mmHg)  in  patients  with  cirrhosis 
was 6%, which is lower than the results in the study 
by Castro et al. (23); it occurs in patients with portal 
hypertension,  which  is  consistent  with  previous 
reports (24, 25).
In agreement with previous studies (18, 22, 25, 26), 
there was no correlation between PPHTN and the 
severity of liver disease as assessed by the Child-Pugh 
score.
A  moderate  male  predominance  was  found  in 
our study: 1:0.8 (male to female), as has been found 
by others (25, 27, 28), and in contrast to the general 
epidemiology of pulmonary hypertension (29).This 
suggests that factors other than female hormones may 
contribute to portopulmonary hypertension (30).
Another interesting result was the finding of a 
higher proportion of portopulmonary hypertension 
in cryptogenic cirrhosis, compared with patients 
with other types of cirrhosis, 4 out of 6 patients 
(P = 0.04).
Conclusions
A widened alveolar-arterial oxygen gradient was 
detected in 61% of patients, four times more often 
than hypoxia, the latter being associated with the 
severity  of  liver  disease.  In  the  present  study,  the 
prevalence of PPHTN in cirrhotic patients was found 
to be 6%, with a male-to-female ratio of 1.25, and 
a  significant  positive  correlation  with  cryptogenic 
cirrhosis (P = 0.04).Hepatitis Monthly, Spring 2010; 10(2): 105-109
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